RISK WATCHYahoo Finance • 13h ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
Why CLPT Stock slipped -0.19% Today — RQD Quant Desk Flash
$10.67 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.65
ClearPoint Neuro Inc. (CLPT) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $342.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CLPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #1000 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CLPT compare to TMCI and EMBC in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, TMCI (Treace Medical Concepts Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -32.4%, cap $329.1M) and EMBC (Embecta Corp.) posts a B grade (74/100 RQD, P/E 3.9x, ROIC 35.5%, cap $371.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CLPT?
▼
Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.65 (-0.22%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLPT)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY CLPT SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (32% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.3% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$10.20-10.1% Next Q
15
Q2 (-2Q)Grade E$9.17-1.4% Next Q
16
Q3 (-1Q)Grade E$9.04+18% Next Q
18
CurrentGrade E$10.67-12% Hist 90D α
19
Trajectory: E (15) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CLPT Turnaround Squeeze
While CLPT currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.41) and Max Pain ($11.20) forces dealer call-delta covering toward $25.99.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CLPT Stock slipped -0.19% Today — RQD Quant Desk Flash
ClearPoint Neuro Inc. (CLPT) slipped -0.19% to $10.67, trading at 15% of its 52-week range ($8.27 – $24.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($8.27 – $24.75) with RSI-14 at 49.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.3% around $10.67 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 61.4% gross margin and $0 annual free cash flow.
Live CLPT Headlines & Catalysts
MARKET WIREwww.debelegger.nl • 16h ago
Clearpoint Neuro (CLPT) Stock Price, Chart & Analysiswww.debelegger.nl report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 19h ago
ClearPoint Neuro (CLPT) Reports Q3 Revenue Growth, Eyes Gene TheGuruFocus report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 22h ago
ClearPoint Neuro Q3 2026 Earnings Call TranscriptBenzinga report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
ClearPoint Neuro (CLPT) Q3 Results Spotlight Cash Runway And Loss PressureSimply Wall St report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHPluang • 1d ago
Lawsuit probes ClearPoint Neuro over stock drop after Huntington's drug trial setbackPluang report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.dars.gov.et • 1d ago
ClearPoint Neuro (CLPT) Edges Lower to $10.67, Holding Above $10.14 Support - Narrow Range Breakoutwww.dars.gov.et report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHPluang • 1d ago
ClearPoint stock drops 23% after Huntington's t...Pluang report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
ClearPoint Neuro, Inc. Q3 2026 Earnings Call SummaryMoby summary of ClearPoint Neuro, Inc.'s Q3 2026 earnings call
MARKET WIREBenzinga • 4d ago
Stifel Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18Stifel analyst Mathew Blackman maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $22 to $18.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLPT)
- ✓Walkthrough of CLPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CLPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.56%▼ DESCENDING CHANNEL
2026-11-02O $10.56H $10.69L $10.56C $10.67VOL 1.25M
RES: $14.95SUP: $8.82SMA50: $12.41SMA200: $12.94
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CLPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +17.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CLPT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CLPT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLPT)
Health Care Rank #1000 of 1016
⚔️ TMCI vs CLPT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CLPT vs. TMCI, EMBC, MOBI, ANIK)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ClearPoint Neuro Inc. (CLPT) ranks #1000 by composite RQD confidence (19/100, grade E) and #505 by equity capitalization ($342.7M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CLPT at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLPT
ACTIVE
ClearPoint Neuro Inc. | E | 19/100 | — | 61.4% | -35.0% | -0.19% | $342.7M | Benchmark Subject |
| TMCI Treace Medical Concepts Inc. | D- | 40/100 | — | 79.8% | -32.4% | -12.45% | $329.1M | /tmci-vs-clpt → |
| EMBC Embecta Corp. | B | 74/100 | 3.9x | 62.6% | 35.5% | -4.73% | $371.7M | /embc-vs-clpt → |
| MOBI Mobia Medical Inc. | D+ | 53/100 | — | — | — | -6.12% | $375.2M | /mobi-vs-clpt → |
| ANIK Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | -3.85% | $291.6M | /anik-vs-clpt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285550In its most recent audited fiscal period (FY2025, filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported GAAP revenue of $37.0M (+17.8% vs. FY2024 revenue of $31.4M , and +54.3% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of -$23.9M, and free cash flow of -$24.4M (-164.7% YoY). On the balance sheet, CLPT closed FY2025 with $97.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $37.0M | -$25.5M | -$23.9M | -$24.4M | $97.7M | — |
| FY2024 (FY) | 2024-12-31 | $31.4M | -$18.9M | -$8.9M | -$9.2M | $39.2M | — |
| FY2023 (FY) | 2023-12-31 | $24.0M | -$22.1M | -$13.7M | -$13.7M | — | — |
3. CLPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #1000 in composite RQD confidence.
How does CLPT compare to TMCI and EMBC in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, TMCI (Treace Medical Concepts Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -32.4%, cap $329.1M) and EMBC (Embecta Corp.) posts a B grade (74/100 RQD, P/E 3.9x, ROIC 35.5%, cap $371.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CLPT?
Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CLPT trading relative to its 50-day, 200-day, and 52-week technical levels?
CLPT last traded at $10.67 (-0.19% on volume of 916,551 shares), positioning the stock -14.02% below its 50-day simple moving average ($12.41) and -17.54% below its 200-day simple moving average ($12.94). Across its 52-week range of $8.27 to $24.75, CLPT sits at the 14.6% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($9.36 to $11.98).
CLPT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CLPT stock moving today?
Why CLPT Stock slipped -0.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 19/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CLPT — ClearPoint Neuro Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:09Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CLPT scores 19 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 2 / 20 (ROIC -35%; FCF yield -7.13%), indicating the business is not currently generating returns on capital or positive free cash flow. The Whale 13F Flow pillar scores 5 / 20 for institutional accumulation and options positioning, the Insider Conviction pillar scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, and the Macro Regime Fit pillar scores 3 / 20 (Beta 1.0; sector sensitivity). The Forensic Balance Sheet pillar scores 6 / 20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5), which is the weakest structural signal in the financial-distress assessment. For a prospective investor, the upside case rests on the reported gross margin of 61.4% and the revenue growth shown across FY 2023 to FY 2025, but the rating places more weight on negative operating economics, low Altman Z-Score reading, and weak insider and institutional support. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data; the stock's positioning within its $8.27 - $24.75 52-week range and $342.7M market capitalization should be read against these forensic signals. This analysis is educational and not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $37.0M | $-24.2M | $-25.5M | N/A | $-24.4M | $45.9M | N/A |
| FY 2024 | $31.4M | $-19.7M | $-18.9M | N/A | $-9.2M | $20.1M | N/A |
| FY 2023 | $24.0M | $-22.4M | $-22.1M | N/A | $-13.7M | N/A | N/A |
Per the SEC financials, operating and net losses persisted across all three reported periods, with operating margin at -60% and net margin at -60% per the market data section. Gross margin is reported at 61.4%. ROIC is -35% per the market data section and the Roarable RQD rating. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9 per the Forensic Balance Sheet pillar. Debt/Equity is 0.5 per the same pillar, while debt values in the SEC financials are N/A.
Recent Catalysts & News Wire Analysis
- RISK WATCH (RED): A Yahoo Finance report headlined that CLPT reported a Q3 loss and missed revenue estimates.
- MARKET WIRE (YELLOW): A www.debelegger.nl report carried a general stock price and chart headline.
- CATALYST (GREEN): A GuruFocus report headlined revenue growth in Q3 and a reference to a gene-related item.
- MARKET WIRE (YELLOW): A Benzinga report carried the Q3 2026 earnings call transcript headline.
- RISK WATCH (RED): A Simply Wall St report headlined cash runway and loss pressure.
- RISK WATCH (RED): A Pluang report headlined a lawsuit probing CLPT over a stock drop following a Huntington's drug trial setback.
The Butterfly Supply-Chain Graph reports sector Health Care, industry Medical/Dental Instruments, supply chain NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the FY 2025 debt balances, given that debt is reported as N/A across all periods?
- What EPS, P/E, and EV/EBITDA figures apply, since these are not available in source data?
- What is the outcome of the lawsuit referenced in the Pluang report, and what is its potential financial exposure?
- What is the company's cash runway given the FY 2025 FCF of $-24.4M against $45.9M cash?
- What drove the FY 2025 revenue increase and does it reflect durable demand?
CLPT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ClearPoint Neuro Inc. (CLPT) • Click "Debate This Headline" to argue it in the Roar Pit below
🔴 RISK WATCH Yahoo Finance • 13h ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates Yahoo Finance report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.debelegger.nl • 16h ago
Clearpoint Neuro (CLPT) Stock Price, Chart & Analysis www.debelegger.nl report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 19h ago
ClearPoint Neuro (CLPT) Reports Q3 Revenue Growth, Eyes Gene The GuruFocus report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 22h ago
ClearPoint Neuro Q3 2026 Earnings Call Transcript Benzinga report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
ClearPoint Neuro (CLPT) Q3 Results Spotlight Cash Runway And Loss Pressure Simply Wall St report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Pluang • 1d ago
Lawsuit probes ClearPoint Neuro over stock drop after Huntington's drug trial setback Pluang report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.dars.gov.et • 1d ago
ClearPoint Neuro (CLPT) Edges Lower to $10.67, Holding Above $10.14 Support - Narrow Range Breakout www.dars.gov.et report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Pluang • 1d ago
ClearPoint stock drops 23% after Huntington's t... Pluang report covering ClearPoint Neuro Inc. (CLPT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CLPT Bull vs. Bear Conversation Board — What's Your Call at $10.67?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLPT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $9.41 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CLPT (E • RQD 19/100) a Buy at $10.69?
Welcome to the CLPT (ClearPoint Neuro Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $8.77 (-18.0%)
Spot @ $10.69 Pump the brakes on CLPT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CLPT, but look at what you are paying: current EV/EBITDA multiples with 61.4% gross margins. Unless ClearPoint Neuro Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $13.47 (+26.0%)
Spot @ $10.69 CLPT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CLPT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $10.69 (52-wk range $8.27 - $24.75), any beat on forward guidance forces shorts and underweight funds to chase.